We describe a case of acute myeloid leukemia with NPM1 mutation and disseminated leukemia cutis in a very old patient, who achieved a long-lasting response to the azacitidine/venetoclax combination with molecular complete remission, given the potential value of this rarely observed clinical outcome.

Osmola M, Gierej B, Kłosowicz A, Waszczuk-Gajda A, Basak GW, Jędrzejczak WW, et al. Leukaemia cutis for clinicians, a literature review. Postepy Dermatol Alergol. 2021 Jun;38(3):359–65.
Scaramucci L, Niscola P, Fratoni S, Giovannini M, Cupelli L, Tendas A, et al. Multicentric myeloid/NK sarcoma in an aleukemic patient evolved in refractory acute leukemia. Leuk Res. 2009 Sep;33(9):1294–6.
Demir D, Hekimgil M, Karaca E, Ulusoy Y, Özdemir HH, Saydam G, et al. Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study. J Clin Pathol. 2023 Apr;76(4):244–51.
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2021 May;47:100773.
Katagiri T, Ushiki T, Masuko M, Tanaka T, Miyakoshi S, Fuse K, et al. Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: a case report and literature review. Medicine. 2017 Sep;96(36):e7975.
Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, et al. Managing myelodysplastic syndromes in very old patients: a teaching case report. Clin Interv Aging. 2013;8:391–4.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29.
Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, et al. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Sep 15;128(21):3880–7.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.
Sharma N, Liesveld JL. NPM 1 mutations in AML-the landscape in 2023. Cancers. 2023 Feb 12;15(4):1177.
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 Mar 12;135(11):791–803.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022 Mar 10;40(8):855–65.
Niscola P, Tendas A, Scaramucci L, Giovannini M, Cupelli L, Fratoni S, et al. Gingival myeloid sarcoma in myelodysplastic syndrome. Support Care Cancer. 2013 Apr;21(4):917–8.
Findakly D, Amar S. A rare case of leukemia cutis as the first presentation of a myelodysplastic syndrome to acute myeloid leukemia transformation. Cureus. 2020 Jun 19;12(6):e8698.
Zhu LX, Chen RR, Wang LL, Sun JN, Zhou D, Li L, et al. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Support Care Cancer. 2022 Aug;30(8):7031–8.
You do not currently have access to this content.